Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Short position
Paradigm Biopharmaceuticals (ASX:PAR) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 593,492 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.09 percentage points. Its highest recorded short interest was 4.77% in March 2022. PAR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Paradigm Biopharmaceuticals (PAR) short interest history
PAR Short Interest History
- 30-day change
- +0.02pp
- 90-day change
- +0.09pp
- 1-year change
- +0.02pp
- All-time high
- 4.77% (March 2022)
- All-time low
- 0.00% (July 2026)
Is PAR heavily shorted?
Not especially: 0.09% short interest is modest by ASX standards, ranking #453 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has PAR's short interest changed recently?
Over the past 30 days Paradigm Biopharmaceuticals's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.09% of shares on issue.
What is the highest PAR's short interest has been?
Since 2019, Paradigm Biopharmaceuticals's short interest peaked at 4.77% in March 2022 and bottomed at 0.00% in July 2026.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2019. See our methodology.